The development of chimeric antigen receptor T (CAR-T) cell therapy, a specific type of
immunotherapy, in recent decades was a fantastic breakthrough for the treatment of …

Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall
survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase …

The Lazarus effect is a rare condition that happens when someone seemingly dead shows
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …

Bispecific T cell engagers (BiTEs) are bispecific antibodies that redirect T cells to target
antigen-expressing tumors. We hypothesized that BiTE-secreting T cells could be a valuable …

Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to
successful chimeric antigen receptor (CAR) T cell therapies in solid tumors including …

Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …

Chimeric antigen receptor (CAR) T cells have shown significant efficacy in hematological
diseases. However, CAR T therapy has demonstrated limited efficacy in solid tumors …

Epidermal growth factor receptor (EGFR) is overexpressed in various cancers, including non-
small cell lung cancer (NSCLC), and in some somatic cells at a limited level, rendering it an …

Chimeric antigen receptor T-cell therapies have transformed the management of
hematologic malignancies but have not yet demonstrated consistent efficacy in solid tumors …

Glioblastoma is the most common malignant primary brain tumor in adults. The prognosis is
extremely poor even with standard treatment of maximal safe resection, radiotherapy, and …